UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe hidradenitis suppurativa (HS). BIMZELX, the ...
News-Medical.Net on MSN
New imaging technique maps medication distribution across skin layers
A new study by the Hebrew University has developed a rapid imaging method that reveals how drugs move through the skin, in ...
Trump rebukes Putin over Russia's nuclear-powered missile test, SNAP benefits set to run out, and more Length: Long Speed: 1.0x President Donald Trump on Monday took aim at Russia’s announcement that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback